Streamex Corp.(STEX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,690 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in STEX
Events flagged as statistical outliers against STEX's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-16
STEX quality score jumped 14 points (11→25) on a new filing
View source filing →
STEX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Streamex Corp. (STEX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STEX at 24.5/100 on a 32-signal composite quality model, placing it at rank #2,690 of 2,960 stocks — the bottom half of the AI-ranked universe. STEX scores in the top quartile across revenue growth (96.2). Areas of concern include profitability (0.1) and balance sheet strength (0.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Streamex Corp. reports quarterly revenue of $146.0K, net income of $-14.6M. Top institutional holders of STEX by reported 13-F value include Legacy Wealth Managment, VANGUARD CAPITAL MANAGEMENT, Yorkville Advisors Global, based on the most recent SEC filings. STEX trades on the Nasdaq exchange and files with the SEC under CIK 1530766. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STEX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Streamex Corp. directly from SEC EDGAR. Streamex Corp.'s 13F Pro composite quality score has ranged between 8 and 29 since 2026, currently 24.5 — a stable long-term trajectory across 22 quarterly and live scoring snapshots.
Revenue
Q2 2026
$146.0K
Net Income
Q2 2026
$-14.6M
ROIC
Q2 2026
-41.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-4379.9% YoYOperating Income
-452.7% YoYEPS (Diluted)
-1186.7% YoYTotal Assets
+22173.5% YoYOp. Cash Flow
-119.4% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $40.0K +122.2% | $18.0K -93.7% | $286.0K -35.1% | $441.0K | $0.00 |
| Net Income | $-462.8M -4379.9% | $-10.3M +64.4% | $-29.0M -7.4% | $-27.1M +15.2% | $-31.9M +38.9% | $-52.2M |
| Operating Income | $-71.1M -452.7% | $-12.9M +54.9% | $-28.5M -4.6% | $-27.3M +18.4% | $-33.4M +43.5% | $-59.2M |
| EPS (Diluted) | $-4.83 -1186.7% | $-0.38 +81.0% | $-1.98 -649.0% | $-0.26 | — | — |
| Total Assets | $187.5M +22173.5% | $842.0K -53.2% | $1.8M -56.3% | $4.1M -73.5% | $15.5M -48.9% | $30.4M |
| Operating Cash Flow | $-10.4M -119.4% | $-4.8M +72.5% | $-17.3M +20.2% | $-21.7M +17.8% | $-26.4M +0.8% | $-26.6M |
| Free Cash Flow | — | — | $-17.5M +20.0% | $-21.9M +18.8% | $-26.9M -0.9% | $-26.7M |
AI Insight: STEX Financial Trends
Streamex is pre-revenue with accelerating cash burn and a massive Q4 2025 accounting charge that has depleted equity.
• Revenue remains at or near $0M across all periods. Operating losses persist, ranging from $1M to $42M quarterly.
• Operating cash outflow widened to $12M in Q2 2026, the worst quarter on record, indicating mounting operational cash consumption.
• Equity swung from negative to $133M in Q4 2025 (likely accounting adjustment), then stabilized near $146M in Q2 2026.
⚠ Q4 2025 net loss of $424M signals a major non-cash charge or impairment; clarify nature and recurrence risk.
⚠ No revenue generation after 18 months of operations. Cash runway and path to commercial viability critical unknowns.
AI Insight: STEX Ratio Trends
Streamex is destroying shareholder value: ROIC collapsed to -41.6% in Q2 2026, while ROE and ROA remain deeply negative.
• ROIC deteriorated from -89.9% in Q1 2026 to -41.6% in Q2 2026, but remains severely impaired versus TTM -67.8%.
• ROA improved from -74.3% in Q2 2025 to -36.5% in Q2 2026, showing sequential progress but still unprofitable.
• ROE worsened to -40.0% in Q2 2026 from -117.5% in Q1 2026, indicating persistent operational distress.
⚠ All profitability metrics remain deeply negative; no visibility into return to positive ROIC, ROA, or ROE.
⚠ Lack of operating margin and net profit margin data limits ability to diagnose root cause of value destruction.
Get alerted when STEX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Streamex Corp. including:
Top Institutional Holders of STEX
Legacy Wealth Managment, LLC/ID
$5.6M6,530,074 shVANGUARD CAPITAL MANAGEMENT LLC
$3.3M3,831,200 shYorkville Advisors Global, LP
$3.2M3,750,000 shGEODE CAPITAL MANAGEMENT, LLC
$1.1M1,257,054 shBlackRock, Inc.
$793.4K933,112 shCambridge Investment Research Advisors, Inc.
$732.0K860,672 shVANGUARD FIDUCIARY TRUST CO
$537.2K631,990 shSTATE STREET CORP
$513.6K603,990 shRENAISSANCE TECHNOLOGIES LLC
$402.7K473,603 shRossby Financial, LCC
$327.4K385,030 sh
| Fund | Value | Shares |
|---|---|---|
| Legacy Wealth Managment, LLC/ID | $5.6M | 6,530,074 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.3M | 3,831,200 |
| Yorkville Advisors Global, LP | $3.2M | 3,750,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.1M | 1,257,054 |
| BlackRock, Inc. | $793.4K | 933,112 |
| Cambridge Investment Research Advisors, Inc. | $732.0K | 860,672 |
| VANGUARD FIDUCIARY TRUST CO | $537.2K | 631,990 |
| STATE STREET CORP | $513.6K | 603,990 |
| RENAISSANCE TECHNOLOGIES LLC | $402.7K | 473,603 |
| Rossby Financial, LCC | $327.4K | 385,030 |
Companies Similar to STEX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
SERA PROGNOSTICS, INC.
Lyell Immunopharma, Inc.
CRESCENT BIOPHARMA, INC.
FATE THERAPEUTICS INC
Arcellx, Inc.
Scilex Holding Co
Metagenomi Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put STEX on your watchlist
Track score changes the day Streamex Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is STEX a good stock to buy?
13F Pro's AI-powered analysis of Streamex Corp. (STEX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STEX are available on the STEX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. STEX is classified as a small company.
Which hedge funds own STEX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STEX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Streamex Corp.'s investment landscape.